TAMPA, Fla. Sept. 09, 2024 - Pacira BioSciences, Inc. a leading player dedicated to non-opioid pain management and regenerative health solutions, recently announced the provision of inducement awards to 17 new employees on September 4, 2024. These awards were granted under Pacira’s Amended and Restated 2014 Inducement Plan with the intention of enticing these employees to join the company. The Compensation Committee of the Board of Directors duly approved these awards in compliance with Nasdaq Listing Rule 5635(c)(4).
Simultaneously, Pacira BioSciences Inc’s stock has witnessed a commendable gain of 7.96% over the past five trading days. Moreover, the company’s revenue per employee has displayed promising growth over the trailing twelve months, accumulating to an impressive $545,883. Specifically, the second quarter of 2024 experienced a 11.03% YoY revenue increase, reaching a cumulative value of $679 million, marking an all-time high for the company.
At present, Pacira BioSciences Inc boasts a workforce of 1,243 employees. However, when compared to its peers in the Healthcare sector, the company’s revenue per employee falls behind 31 other companies. Despite this, it is worth noting that Pacira BioSciences Inc’s overall ranking has declined from the first quarter of 2024.
These recent developments signify Pacira BioSciences Inc’s proactive approach in bolstering its workforce by attracting skilled professionals through inducement awards. Furthermore, the notable revenue growth reflects the company’s dedication to creating innovative solutions while remaining committed to non-opioid pain management.
Comments